Sotagliflozin : a combined SGLT1/SGLT2 inhibitor to treat diabetes
INTRODUCTION: Sotagliflozin is the first dual SGLT1/SGLT2 inhibitor developed for use in diabetes. The agent blocks SGLT2 in the kidneys and SGLT1 in the intestines resulting in reduced early phase glucose absorption and increased blood levels of GLP-1. Initial studies were directed at type 1 diabetes. Areas covered: The published information on sotagliflozin is reviewed, along with the results of several pivotal Type 1 diabetes trials. Expert opinion: Sotagliflozin treatment lowers HbA1c and reduces glucose variability in Type 1 diabetes patients. Several other SGLT2 inhibitors have been associated with a tendency to diabetic ketoacidosis (DKA). In the type 1 trials, sotagliflozin treated individuals experienced DKA at a higher rate than placebo treated patients. An additional safety concern arises from the as yet unknown potential risks in women of child bearing potential. The sotagliflozin development program has now been extended to trials in type 2 diabetes. In type 2 diabetes, long-term studies will be needed to assess the benefits and risks of the agent as a possible alternative to currently marketed SGLT2 inhibitors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Expert review of endocrinology & metabolism - 13(2018), 6 vom: 16. Nov., Seite 333-339 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rendell, Marc S [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 25.09.2019 Date Revised 25.09.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/17446651.2018.1537779 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM290126959 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM290126959 | ||
| 003 | DE-627 | ||
| 005 | 20231225064045.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/17446651.2018.1537779 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0967.xml |
| 035 | |a (DE-627)NLM290126959 | ||
| 035 | |a (NLM)30379091 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rendell, Marc S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sotagliflozin |b a combined SGLT1/SGLT2 inhibitor to treat diabetes |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.09.2019 | ||
| 500 | |a Date Revised 25.09.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Sotagliflozin is the first dual SGLT1/SGLT2 inhibitor developed for use in diabetes. The agent blocks SGLT2 in the kidneys and SGLT1 in the intestines resulting in reduced early phase glucose absorption and increased blood levels of GLP-1. Initial studies were directed at type 1 diabetes. Areas covered: The published information on sotagliflozin is reviewed, along with the results of several pivotal Type 1 diabetes trials. Expert opinion: Sotagliflozin treatment lowers HbA1c and reduces glucose variability in Type 1 diabetes patients. Several other SGLT2 inhibitors have been associated with a tendency to diabetic ketoacidosis (DKA). In the type 1 trials, sotagliflozin treated individuals experienced DKA at a higher rate than placebo treated patients. An additional safety concern arises from the as yet unknown potential risks in women of child bearing potential. The sotagliflozin development program has now been extended to trials in type 2 diabetes. In type 2 diabetes, long-term studies will be needed to assess the benefits and risks of the agent as a possible alternative to currently marketed SGLT2 inhibitors | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Gene knockout models | |
| 650 | 4 | |a SGLT1 | |
| 650 | 4 | |a SGLT2 | |
| 650 | 4 | |a dapligliflozin | |
| 650 | 4 | |a diabetic ketoacidosis | |
| 650 | 4 | |a empagliflozin | |
| 650 | 7 | |a Glycosides |2 NLM | |
| 650 | 7 | |a Sodium-Glucose Transporter 2 Inhibitors |2 NLM | |
| 650 | 7 | |a (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol |2 NLM | |
| 650 | 7 | |a 6B4ZBS263Y |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of endocrinology & metabolism |d 2006 |g 13(2018), 6 vom: 16. Nov., Seite 333-339 |w (DE-627)NLM191111503 |x 1744-8417 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2018 |g number:6 |g day:16 |g month:11 |g pages:333-339 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/17446651.2018.1537779 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2018 |e 6 |b 16 |c 11 |h 333-339 | ||